Treatment with Interferon plus Ribavirin in anti-HIV Negative Patients with Congenital Coagulation Disorders and Chronic Hepatitis C

Summary

Background

Hepatitis C virus (HCV) infected hemophiliacs respond at low rate to interferon (IFN) monotherapy.

Aims

To assess efficacy of IFN and RBV in HIV negative hemophiliacs with chronic hepatitis C and identify early predictive factors of response.

Methods

Twenty naive patients were treated with interferon and RBV for twelve months. Response was assessed by both serial ALT and HCV RNA levels.

Results

Normalization of ALT with clearance of HCV RNA occurred in seven (35%) patients. Age and age at infection were the only features associated with a higher likelihood of response. In all responders the viral load had decreased by at least one log within two months of starting treatment.

Conclusions

Combination of interferon and ribavirin is well tolerated by hemophiliacs who achieve similar sustained response rates to non-hemophiliacs. Quantitative assessment of viral load at two months of treatment is a useful method to identify non-responders at an early stage.

Keywords

HCV - interferon - ribavirin - clotting disorders

• References

• 1 Tedder RS, Briggs M, Ring C, Tuke PW, Jones P, Savidge GF, Rodgers B, Garson JA. Hepatitis C antibody profile and viremia prevalence in adults with severe haemophilia. Br J Haematol 1991; 79: 512-5.
• 2 Watson HG, Ludlam CA, Rebus S, Zhang LQ, Peutherer JF, Simmonds P. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with nonvirus inactivated factor VIII and IX concentrates. Br J Haematol 1992; 80: 514-8.
• 3 Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-52.
• 4 Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31.
• 5 Mannucci PM. Effects of factors VIII concentrates on the immune system of patients with haemophilia. Thromb Haemost 1995; 74: 437-9.
• 6 Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994; 170: 1018-22.
• 7 Peerlinck K, Willems M, Sheng L, Nevens F, Fevery J, Yap SH, Vermylen J. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response. Br J Haematol 1994; 86: 816-9.
• 8 Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G, Lee C. Alpha interferon for hepatitis C virus infection in hemophilic patients. Haemophilia 1995; 01: 54.
• 9 Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, Robert L, Simmonds P, Ludlam CA. Interferon treatment for chronic hepatitis C infection in hemophiliacs-Influence of viral load, genotype and liver pathology on response. Blood 1996; 87: 1704-9.
• 10 Rumi MG, Sanagostino E, Morfini M, Gringeri A, Tagariello G, chistolini A, pomtisso P, Tagger A, Comobo M, Mannucci PM. A multicenter controlled, randomized, open trial of interferon a-2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Blood 1997; 89: 3529-33.
• 11 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
• 12 Consensus Statement. EASL International Consensus Conference on Hepatitis. C. Paris, February 26-28 1999;
• 13 Martell M, Gómez J, Esteban JI, Sauleda S, Quer J, Cabot B, Esteban R, Guardia J. High throughput real-time RT-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999; 37: 327-32.
• 14 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantone J, Green D, Hempton JW, Hilgartner MN, Lazarson J, Levin PH. A more uniform measurement of factor VIII inhibitor. Thromb Res 1975; 34: 869-72.
• 15 Martín A, Luna JD. Bioestadística para las ciencias de la salud. 3rd ed.. Madrid: Ediciones Norma S. A; 1990
• 16 Chemello L, Bonetti P, Cavaletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A. and the TriVeneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
• 17 Reichard O, Norkrans G, Frydén A, Braconier JH, Sönenborg A, Weiland O. Randomised, double’blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
• 18 Davis GL, Esteban R, Rustgi VK, Hoefs J, Gordon SC, Trepo C, Schiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
• 19 Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
• 20 Ampurdanes S, Olmedo E, Maluenda MD, Forns X, Lopez-Labrador FX, Costa J, Sanchez-Tapias JM, de Anta MT, Rodes J. Permanent response to alpha’interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996; 25: 827-32.
• 21 Zeuzem E, Lee J, Franke A, Ruster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-56.